Karthik Achari
Clinician and Founder, PepMD
Karthik Achari is a clinician and founder focused on healthcare and the systems that make it trustworthy. He is the Clinician and Founder of PepMD, an independent standards body developing the credentialing and trust infrastructure for peptide medicine.
Coverage
Record
- Public record
- Submitted formal written public comment under FDA Docket No. FDA-2025-N-6895
- Training
- DNP-FNP candidate, Bradley University
- Background
- Background in pharmaceutical and peptide manufacturing and distribution, and precision diagnostic medicine
01 Currently
Currently
Karthik runs PepMD full time. PepMD credentials clinicians, recognizes compounding pharmacies, and authorizes IRB-governed research sites under a single standard.
02 Work
PepMD
PepMD is an independent standards body developing the credentialing and trust infrastructure for peptide medicine.
01
Clinical credentialing
PepMD credentials providers and prescribers who work with peptides. Credentialing reviews a clinician's license standing, training, and prescribing practice against a published standard, so that a clinician's qualification to work with peptides can be checked rather than taken on trust.
02
Pharmacy recognition
PepMD recognizes compounding pharmacies. Recognition examines how a pharmacy sources material, documents its processes, and tests what it dispenses, so that the quality decisions behind a compounded peptide are visible to the clinicians and patients who depend on them.
03
Research site authorization
PepMD authorizes IRB-governed research sites. Authorization confirms that a site operates under institutional review board oversight and follows a documented protocol, so that peptide research conducted at that site can be identified as governed research.
03 Media
Media and commentary
· FDA Pharmacy Compounding Advisory Committee, White Oak
Oral comments, FDA Pharmacy Compounding Advisory Committee Open Public Hearing, White Oak, July 2026
· Healthline
GLP-1 medications and performance enhancing use
04 Writing
Writing
What the July 2026 PCAC Votes Did and Did Not Do
The July 2026 votes of the FDA's Pharmacy Compounding Advisory Committee were advisory recommendations, not final agency action. Formal notice-and-comment rulemaking must follow before any change carries legal effect.
Why Peptide Medicine Needs a Standards Layer
Peptide medicine has grown faster than the structures meant to keep it accountable. This piece describes the gap between what is legal and what is verifiable.
05 Questions
Questions and answers
- Who is Karthik Achari?
- Karthik Achari is a clinician and founder focused on healthcare and the systems that make it trustworthy. He is the Clinician and Founder of PepMD, an independent standards body developing the credentialing and trust infrastructure for peptide medicine. A clinician by training, he is completing Bradley University's Doctor of Nursing Practice, Family Nurse Practitioner program.
- What is PepMD?
- PepMD is an independent standards body developing the credentialing and trust infrastructure for peptide medicine. It credentials clinicians, recognizes compounding pharmacies, and authorizes IRB-governed research sites under a single standard.
- What does PepMD recognition mean?
- PepMD recognition means a clinician, pharmacy, or research site has met PepMD's standard. Recognition means qualification is verifiable rather than assumed.
- What did the July 2026 FDA advisory committee votes on peptides mean?
- The July 2026 votes were advisory recommendations by the FDA's Pharmacy Compounding Advisory Committee, not FDA approval. Formal notice-and-comment rulemaking follows before any recommendation carries legal effect.
- Is PepMD affiliated with any pharmaceutical company or peptide seller?
- No. PepMD is an independent standards body developing the credentialing and trust infrastructure for peptide medicine. It does not sell peptides and takes no position on any product. Karthik Achari has fully divested his prior commercial interests and runs PepMD full time.
